Skip to main content
Welcome to
super saver spring
offer ends april 20
save over $140
save over 85%
$0.99
per week for 24 weeks
Welcome to
super saver spring
$0.99
per week
for 24 weeks
// //

Aurinia Pharmaceuticals Inc TSX: AUP-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

Today's Trading

Day Low 15.92
Day High 16.32
Open:16.29
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Strong Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Aurinia Presents Data Demonstrating LUPKYNIS(TM) (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
- BusinessWire - Thu Apr 8, 5:05AM CDT
BusinessWire - CMTX
Thu Apr 8, 5:05AM CDT
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS(TM) (voclosporin) in lupus nephritis (LN). The data were shared at the National Kidney Foundation (NKF) 2021 Spring Clinical Meetings by Anca D. Askanase, M.D., M.P.H., Founder and Director of Columbia University Irving Medical Center's Lupus Center and the Director of Rheumatology Clinical Trials.
Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS(TM) (voclosporin) in Latest ICER Draft Evidence Report
- BusinessWire - Mon Mar 15, 5:05AM CDT
BusinessWire - CMTX
Mon Mar 15, 5:05AM CDT
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today announced a favorable assessment regarding the cost-effectiveness and value of LUPKYNIS(TM) (voclosporin), based on an independent analysis issued by the Institute for Clinical and Economic Review (ICER) in a revised Evidence Report issued on March 12, 2021. The report finds that LUPKYNIS represents an important new treatment option for patients living with lupus nephritis (LN) and at the estimated net price, determined the therapy to be priced in alignment with ICER's recommended health-benefit price benchmark ranges.
Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences
- BusinessWire - Tue Mar 2, 5:05AM CST
BusinessWire - CMTX
Tue Mar 2, 5:05AM CST
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the executive management team will participate in multiple upcoming investor conferences including the:
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 15.18 +5.60% increase
on 03/25/21
Period Open:16.59
Price movement based on the high, low and last over the given period.
18.05 -11.19% decrease
on 03/16/21
-0.56 (-3.38%) decrease
since 03/09/21
3-Month 15.18 +5.60% increase
on 03/25/21
Period Open:16.98
Price movement based on the high, low and last over the given period.
26.00 -38.35% decrease
on 01/25/21
-0.95 (-5.59%) decrease
since 01/08/21
52-Week 15.18 +5.60% increase
on 03/25/21
Period Open:21.24
Price movement based on the high, low and last over the given period.
26.23 -38.89% decrease
on 05/12/20
-5.21 (-24.53%) decrease
since 04/09/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies